Hepatitis C Direct Antiviral Drugs and Hepatic Decompensation in Patients with Advanced Cirrhosis: Culprit or Innocent Bystander?

Digestive Diseases and Sciences

Volumn 60, Issue 4, 2015, Pages 806-809

  Saxena, Varun ^a   Terrault, Norah A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FUSED HETEROCYCLIC RINGS; PROTEINASE INHIBITOR; SULFONAMIDE;

COMPLICATION; DRUG-INDUCED LIVER INJURY; HEPATITIS C, CHRONIC; HUMAN; LIVER CIRRHOSIS; MALE;

DRUG-INDUCED LIVER INJURY; HEPATITIS C, CHRONIC; HETEROCYCLIC COMPOUNDS, 3-RING; HUMANS; LIVER CIRRHOSIS; MALE; PROTEASE INHIBITORS; SULFONAMIDES;

EID: 84939986010     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-015-3535-x     Document Type: Editorial

References (12)

1. Lawitz E, Sulkowski MS, Ghalib R, et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet. 2014;384:1756–1765.
2. Stine JG, Intagliata N, Shah NL, et al. Hepatic decompensation likely attributable to simeprevir in patients with advanced cirrhosis. Dig Dis Sci. (Epub ahead of print). doi:10.1007/s10620-014-3422-x
3. Danan G, Benichou C. Causality assessment of adverse reactions to drugs–I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol. 1993;46:1323–1330.
4. Sofosbuvir [package insert]. Foster City, CA: Gilead Sciences; 2013.
5. Simeprevir [package insert]. Titusville, NJ: Janssen Therapeutics; 2013.
6. Dienstag JL, Ghany MG, Morgan TR, et al. A prospective study of the rate of progression in compensated, histologically advanced chronic hepatitis C. Hepatology. 2011;54:396–405.
7. Kamath PS, Kim WR. Advanced Liver Disease Study G. The model for end-stage liver disease (MELD). Hepatology. 2007;45:797–805.
8. Jensen DM, O’Leary JG, Pockros PJ, et al. Safety and efficacy of sofosbuvir-containing regimens for hepatitis C: real-world experience in a diverse, longitudinal observational cohort [abstract]. In: Program and Abstracts of the 65th Annual Meeting of the American Association for the Study of Liver Diseases, 7–11 November 2014, Boston, MA, Abstract 45.
9. Aqel B, Pungpapong S, Werner TK, et al. The use of simeprevir and sofosbuvir to treat HCV G1 in the liver transplant setting: The experience in 3 US Centers [abstract]. In: American Association for the Study of Liver Diseases International Conference, 7–11 November 2014, Boston, MA, Abstract 19.
10. Modi AA, Nazario H, Gonzalez SA, et al. Safety and efficacy of simeprevir + sofosobuvir with or without ribavirin in patients with decompensated genotype 1 hepatitis C induced cirrhosis [abstract]. In: American Association for the Study of Liver Diseases International Conference, 7–11 November 2014, Boston, MA, Abstract 956.
11. Price J, Terrault NA. Treatment of hepatitis C in liver transplant patients. Liver Transplantation. 2015 (in press).
12. Schiff ER, Lai CL, Hadziyannis S, et al. Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients. Hepatology. 2003;38:1419–1427.